April 5, 2024
Artery is pleased to inform that the Drug Safety and Monitoring Board today concluded that CS6253 was safe and showed favorable pharmacokinetics in the Phase 1 Single Ascending Dose study (n=40), and recommended the transition to the Phase 1 Multiple Ascending Dose Study (NCT05965414).
November 1, 2023
Artery is proud to inform that the ATI-CS-001 study (NCT05965414) has been approved by regulatory authorities, ethics committee with screening commencing November 1, 2023. For more information, please visit https://clinicaltrials.gov/study/NCT05965414.
September 20, 2023
Artery is honored to present at the Boulder Peptide Symposium in Napa Valley, California.
Title: A novel small molecule peptide CS6253 in the treatment of hereditary APOE4-associated dementia including Alzheimer's disease
Symposia: Peptides in the Clinic
Date: September 20, 2023
Session Time: 10.35 – 11.05 (PST)
July 17, 2023
Artery is excited to showcase a poster at the AAIC23 conference in Amsterdam, Netherlands.
Title: P2-686 - UPREGULATING ABCA1-MEDIATED CHOLESTEROL TRANSPORTATION BY CS6253 – OPPORTUNITY FOR CONVENIENT SC ROUTE OF ADMINISTRATION
Symposia: In-Person Poster Monday, Drug Development
Date: July 17, 2023
Session Time: All day
December 1, 2022
Artery has implemented a Financial Conflict of Interest Policy to comply with NIH Grants Policy Statement regulations and guidelines. Each institution that is subject to the Financial Conflict of Interest regulation shall maintain an up-to-date, written, enforced policy on FCOI that complies with the regulation and make the policy available via a publicly accessible Web site. To view Artery's Financial Conflict of Interest Policy please click here.
November 30, 2022
Artery is thrilled to present at CTAD22 conference in San Francisco, USA.
Title: OC26 - Design of the ABCA1 agonist CS6253 Phase 1 SAD and MAD study in male and female, APOE4 and non-APOE4 carriers to assess safety, PK and biomarker efficacy
Symposia: ORAL COMMUNICATIONS’ FOCUS SESSION: Interim or preliminary data and study design
Date: December 2, 2022
Session Time: 11:35 – 11:45 (PST)
July 12, 2022
Artery is pleased to announce a “Part the Clouds" (PTC) award from the Alzheimer’s Association, as one of six world-wide grant recipients. This will allow Artery to perform a larger and more conclusive Phase 1 Multiple Ascending Dose study in elderly subjects with APOE4 and risk of developing Alzheimer’s, with the intention to show safety, pharmacokinetics, and biomarker efficacy. The recent publication of CS6253 effects in cynomolgus monkeys speak to a robust set of biomarker effects aligning with the ABCA1 agonist CS6253 properties. CEO Jan Johansson commented that “Artery is thankful to Alzheimer's Association's PTC grant and it provides additional peer-review validation and non-dilutive funding beyond the NIH-NIA grant received 2021”. For more information see;
https://www.alz.org/news/2022/alzheimers-association-part-the-cloud-grant-progra
June 24, 2022
Artery and Yassine Lab at Keck School of Medicine of USC are happy to report that a peer-reviewed scientific article has been accepted and published as of today in Alzheimer's Research & Therapy. The publication is titled "Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys.” The article describes effects of the ABCA1 agonist peptide CS-6253 on amyloid-β peptides and lipoproteins in plasma and cerebrospinal fluid (CSF) of cynomolgus monkeys. The article may be accessed via https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01028-1.
May 20, 2022
Artery is delighted to announce that the U.S. Food and Drug Administration (FDA) has cleared Artery's investigational new drug (IND) application and notified Artery that the study may proceed. In the IND, Artery include a protocol titled “A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers and in ApoE4 Carriers” that Artery is currently working on and the study is planned to commence in late 2022.
March 16, 2022
Artery is pleased to present at AD/ PD22 conference in Barcelona, Spain.
Title: Treatment with the ABCA1 agonist CS6253 in cynomolgus monkeys increases plasma apolipoprotein E and AB42/40-ratio
Symposia: AD DIAGNOSIS & CLINICAL TRIALS & ADVANCES IN DRUG DEVELOPMENT 3
Date: March 16, 2022
Session Time: 07:00 - 09:15 (CET)
December 24, 2021
Artery is pleased to announce the publication of "Neuronal ROS-induced glial lipid droplet formation is altered by loss of Alzheimer's disease-associated genes" in the Proceedings of the National Academy of Sciences. The collaboration between Artery and Hugo Bellen's lab at Baylor College of Medicine and Texas Children¹s Hospital shows that in a Drosophila model APOE4 vs APOE3 cannot transfer (Reactive Oxygen Species, ROS) lipids from neurons to glial cells, which is remedied by expressing the ABCA1 agonist CS6253 in the neurons. The article may be accessed via; https://www.pnas.org/content/118/52/e2112095118, and a commentary is provided at; https://www.sciencedaily.com/releases/2022/01/220103121721.htm.
September 21, 2021
Artery receives NIH-NIA fast-track SBIR grant to open up IND and perform First in Human testing of the ABCA1 agonist CS6253 indicated for the treatment of hereditary APOE4 associated Alzheimer’s disease.
Artery Therapeutics, Inc (Artery) is pleased to announce that on the World Alzheimer’s Disease Day September 21, 2022 we received a fast-track development grant from National Institutes of Health (NIH) National Institute of Aging (NIA) to perform “first in human testing”.
On the heels of successful toxicology studies with the ABCA1 agonist CS6253, also supported by a NIH-NIA grant, the Small Business Innovation Research (SBIR) fast-track grant was received for opening up the IND (part 1) and performing a Single Ascending Dose (SAD) study (part 2) in 32-40 men and women 50 years and older.
“We are very pleased for the peer-review validation of our technology and its potential in the treatment of hereditary APOE4 associated AD”, Jan Johansson MD, PhD, CEO of Artery stated. “The first in human study will allow us to asses safety, pharmacokinetics, and instant lipoprotein and amyloid effects”, Dr. Johansson further stated.
In mice AD models cholesterol-directed treatment with CS6253, ABCA1was upregulated, apoE4 lipidation increased, amyloid and tau levels decreased and AD reversed. Consistent with the mice studies multiple dosing in monkeys showed unique lipid changes which was associated with transfer of amyloid from brain to plasma.
APOE4 is the strongest genetic risk factor for Alzheimer’s disease and is also over-represented in many other dementia conditions including Parkinson's dementia, fronto-temporal dementia and traumatic brain injury suggesting a general metabolic culprit - lipid transport. APOE4-driven dementia is found in approximately 65% of Alzheimer's patients and more than 3 million patients in the USA alone. In homozygote APOE4 carriers the likelihood of developing AD is increased 12-20 fold. Recent data shows that the apoE4 protein compared to apoE2 and apoE3 has impaired cooperation with its lipidation protein, the ABCA1 transporter. Based on a discovery platform Artery’ has developed a lead molecule CS6253 targeting the ABCA1 transporter that improves the apoE - ABCA1 protein-to-protein interaction and reverses AD.
The content of this news release is solely the responsibility Artery and does not necessarily represent the official views of the National Institutes of Health.
July 26 - 30, 2021
Artery will present a poster in person during AAIC 2021.
Title: CS6253 ABCA1 agonist increases apoA-I subspecies preβ-HDL and lowers Aβ42 and Aβ40 in cerebrospinal fluid in cynomolgus monkeys
Date: July 29
Session Name: Drug Development, nonhuman
Location: Denver Convention Center
Poster # 255
March 8, 2021
Artery is pleased to present at AD/ PD 2021 virtual conference.
Title: CS6253 ABCA1 AGONIST TREATMENT IN JUVENILE CYNOMOLGUS MONKEYS REDUCES CSF AΒ42 AND INCREASES PLASMA AΒ42 IN DOSE-RESPONSE MANNER
Symposia: APOE MECHANISMS AND TREATMENT STRATEGIES
Date: March 13, 2021
Session Time: 10:00a - 12:00p (CET)
February 24, 2021
Artery is presenting at "Longevity Innovations and Neurodegeneration Company Showcase" 12:30 PST, February 24, 2021. Artery is very pleased to have been selected by NIH-NIA to present at the prestigious LINCS meeting "Treatment of apoE4-associated dementia including Alzheimer's disease". The ABCA1 agonist CS6253 just finishing the IND enabling studies and showing favorable drugability features provides a highly differentiated approach to address genetically defined APOE4 associated dementia including Alzheimer's disease. Following the 7 minute presentation a breakout session will follow allowing Q&A.
November 4, 2020
Artery is presenting a poster and short video at CTAD 2020, titled "CS6253 ABCA1 agonist treatment in cynomolgus monkeys reduces cerebrospinal fluid concentrations of Aβ42, Aβ40, APP and AP2B1 in dose-response manner." The authors are J.O. Johansson 1, H.N. Yassine 2, D.M. Michaelson 3, J.E.G. Johansson 4, H. Zetterberg 5, B. Winblad 6, J.L. Cummings 7 1Artery Therapeutics, Inc. - San Ramon, Ca (United States), 2Usc - Los Angeles (United States), 3Tel Aviv University - Tel Aviv (Israel), 4Artery Therapeutics, Inc. - San Ramon (United States), 5U Of Gothenburg - Gothenburg (Sweden), 6Karolinska Institutet - Stockholm (Sweden), 7Unlv - Las Vegas (United States).
May 15, 2020
Artery Therapeutics, Inc (Artery) has been cleared for the second part of its fast-track Small Business Innovation Research (SBIR) grant from the National Institute of Aging (NIA) of the National Institutes of Health (NIH). Artery was awarded an additional $2,375,000 for Phase II activities. The first part of this fast-track award was successfully accomplished by showing favorable pharmacokinetics, pharmacodynamics and safety profile of CS6253 in cynomolgus monkeys. The aim of the Phase II SBIR grant is to complete the IND enabling studies under GLP conditions with the goal of submitting the IND for CS6253 in first half of 2021.
Dr. Johansson, MD, PhD, CEO and Principal Investigator for the grant states “We are very pleased with the CS6253 results in cynomolgus monkeys and are appreciate of NIH-NIA helping us to fast-track the development program of CS6253 in the treatment of apoE4 associated Alzheimer's disease, the main genetic risk factor increasing Alzheimer's risk up to 20-fold.”
Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number R44AG060826. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
October 21, 2019
Artery is pleased to announce the publication of "ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes” in the Journal of Neuroscience. The collaboration between Artery, University of Southern California, Tel Aviv University, University of Washington, and Huntington Medical Research Institute provides critical insights into the interactions among ABCA1, ApoE lipidation and aggregation, and underscores the promise of stabilizing ABCA1 with CS-6253 to prevent ApoE associated disease processes. To access abstract please click here.
July 14 - 17, 2019
Artery and collaborators are presenting two posters at AAIC 2019.
Title: ApoE4 Traps ABCA1 in Endosomes and Impairs Its Cholesterol Efflux Function
Date: July 14
Location: South Hall GH - Los Angeles Convention Center
Poster # P1-188
Title: ABCA1 Activation By CS6253 As a Therapeutic for APOE4-Associated Alzheimer’s Disease
Date: July 17
Location: South Hall GH - Los Angeles Convention Center
Poster # P4-033
June 1, 2019
Artery Therapeutics, Inc (Artery) is pleased to announce that the National Institute of Aging (NIA) of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) fast-track grant to advance "CS6253 for the treatment of apoE4-driven dementia including Alzheimer’s disease". The phase I of this award, to be performed the next 6-9 months will focus on PK and PD assessment in cynomolgus monkey studies in preparation for IND enabling studies. If predefined milestones are met then the Phase II portion of the fast-track grant will focus on completing an IND submission for CS6253.
Dr. Johansson, Founder, Chief Executive Officer of Artery and Principal Investigator for the grant states “cynomolgus monkeys have an apoE with high homology to human apoE4 and already in the phase I part of the grant we hope to assess pharmacokinetics, pharmacodynamics and safety relevant to translation to studies in human apoE4 carriers."
ApoE4 is the strongest genetic risk factor for Alzheimer’s disease and is also over-represented in many other dementias including Parkinson's dementia, fronto-temporal dementia and traumatic brain injury suggesting a general metabolic culprit - lipid transport. ApoE4-driven dementia is found in approximately 60% of Alzheimer's patients and more than 2.5 million patients in the USA alone. The risk in apoE4 homozygote carriers is extra severe and increasing the likelihood to develop Alzheimer’s disease 12-fold. Recent data shows that apoE4 compared to apoE2 and apoE3 has impaired cooperation with its lipidation protein, the ATP Binding Cassette-A1 (ABCA1). Based on a discovery platform Artery’ has developed a lead molecule CS6253 targeting the ABCA1 transporter that improves the apoE - ABCA1 cooperation.
Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number R44AG060826. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
March 27, 2019
Exciting new CS6253 data will be presented at AD/PD 2019 meeting in Lisbon, Portugal.
Oral presentation by Dr. Jan Johansson
Title: Prevention of ABCA1 aggregation and degradation by CS6253 to address apoE4 associated neurodegeneration and Alzheimer's disease
Session: Symposium 03: ApoE mechanisms and treatment strategies
Room: Auditorium VIII
Date: March 27th
Time: 10 AM - 10.15 AM
November 3-7, 2018
Artery is pleased to announce that three abstracts containing new CS6253 data will be presented at Society for Neuroscience annual meeting (SfN2018) in San Diego.
1. Poster presentation by Dr. Ana Valencia from UIC.
Title: ABCA1 activation in the CNS as a therapeutic target for APOE4-induced Alzheimer’s disease risk
Session: Alzheimer's Disease and Other Dementias: Therapeutic Strategies: Preclinical Animal Models III
Room: SDCC Halls B-H
Date: November 6th
Time: 8AM - 12PM
Poster number: 468.14 / J3
2. Oral Presentation by Dr. Hussein Yassine from USC.
Title: New paradigms in treating apoE4-associated Alzheimer’s disease; Proof of concept and translational finding from studies with the ABCA1 agonist therapeutic CS6253
Session: Alzheimer's Disease and Other Dementias: ApoE and Associated Pathways
Room: SDCC 24
Date: November 6th
Time: 1:30 PM - 1:45 PM
3. Oral Presentation by Dr. Varun Rawat, from Dr. Yassine's Lab at USC.
Title: ApoE4 aggregation and hypolipidation is implicated in Alzheimer’s disease pathology in cellular, animal and human studies
Session: Neurotoxicity, Inflammation, and Neuroprotection: Neuroinflammation: Neurodegeneration
Room: SDCC 24
Date: November 7th
Time: 10:00 AM - 10:15 AM
July 25-26, 2018
Dr. Johansson will present an oral abstract and a poster abstract during AAIC 2018 in Chicago.
Poster Abstract Title: ApoE4 Aggregation and Hypolipidation Is Implicated in Alzheimer’s Disease Pathology in Cellular, Animal and Human Studies
Session: Basic and Translational Science
Room: Hall F
Date: Wednesday, July 25th
Time: 9:30 - 16.15
Poster number: P4-242
Oral Abstract Title: New Paradigms in Treating apoE4 Driven Dementia Diseases, Proof of Concept and Translational Findings from Studies with the ABCA1 Agonist Therapeutic CS6253
Session: Cholesterol Regulation and New Targets
Room: 190
Date: Thursday, July 26th
Time: 12.15 - 12-30
Location: McCormick Place, Chicago, IL, USA.
May 11, 2018
Dr. Yassine from Keck School of Medicine of USC will present a poster titled "Cell, Mice and Human CSF Studies Indicate Impaired Interactions Between ABCA-1 and ApoE4 in ApoE4 Driven Alzheimer’s Disease." The poster contains new data from a CS6253 study.
Session: Poster Session II
Room: Imperial Ballroom B
Date: Friday, May 11th
Time: 17:30 - 19.30
Poster number: 399
Location: Hilton San Francisco Union Square, San Francisco, California
April 23, 2018
Dr. Yassine and Dr. Rawat, both are Artery collaborators from Keck School of Medicine of USC will present a biomarker poster related to ABCA1 and apoE3 and apoE4 including human CSF data. The abstract is titled "In vitro, In vivo and cerebrospinal fluid studies implicate decreased ABCA-1 activity with APOE4."
Session: Poster session II, Genetic and Basic Science Studies in Neurodegenerative Diseases
Date: Monday, April 23rd
Time: 11:30 - 19.00
Poster number: 197
March 15, 2018
Dr. Johansson will give an oral presentation at AAT-AD/PD 2018 in Torino, Italy, titled " Novel paradigms in the treatment of apoE4-driven dementias including Alzheimer's disease; proof-of-concept and translational aspects of a selective ABCA-1 agonist therapeutic CS6253."
Session: Symposium 8 - ApoE: Still a target for therapy?
Date: Thursday, March 15th
Time: 18:00 - 18.20
Room: Sala Madrid
November 14, 2017
Dr. Yassine, an Artery collaborator from University of Southern California will present new information regarding CS6253 during the annual Society for Neuroscience's conference.
Title: ABCA-1 agonist treatment as a potential therapeutic for ApoE4 hypolipidation and impaired ABCA-1 activity in Alzheimer’s disease
Date: Tuesday, November 14th
Time: 9:45 - 10.00 AM
Room: 146C Session number and title: 453 - Alzheimer's Disease: Neuroinflammation and Immune Actions
Location: Washington, DC.
November 13, 2017
Dr. Johansson will present a poster titled "ABCA1 Agonist CS6253 Reverses ApoE4-Driven Alzheimer’s Disease with Concomitant Changes in Plasma and Brain ApoE and ApoJ" during American Heart Association Scientific Sessions 2017 in Anaheim, CA.
Poster session: BASC.01 - Best of AHA Specialty Conferences: ATVB/PVD 2017
Date: Monday, November 13th
Time: 10:30 - 11.45 AM
Poster: ATVB15
Room: Science & Technology Hall, Halls A-C, Level 1
October 17, 2017
Dr. Johansson will present during 2017 BIO Investor Forum located at The Westin St. Francis Hotel, San Francisco.
Presentation Date: Tuesday, October 17th
Presentation Time: 9:30 AM
Presentation Room: Yorkshire
Main Therapeutic Focus: CNS/Neurological
August 26 and 28, 2017
Dr. Johansson will present two poster presentations at European Society of Cardiology Congress 2017.
Moderated Poster Title: Atherosclerosis reduction and improved glucose control the ABCA1 agonist CS6253. In vitro and in vivo mechanism of action studies
Poster Session: Vascular degeneration and restoration
Session Date: Saturday, August 26, 2017
Poster: P180
Session Time: 12:35 - 13:25
Location: Moderated poster station - Poster Area
Poster Title: Vascular and Alzheimer's disease effects by the apoE derived ABCA1 agonist CS6253
Poster Session: 5 - Cardiovascular care - Biology II
Session Date: Monday, August 28, 2017
Poster: P4494
Session Time: 14:00 - 18:00
Location: Poster Area
July 16 and 19, 2017
Artery will present two poster presentations at AAIC 2017 in London, UK. The first poster presentation will be presented by Dr. Jan Johansson and is titled "The ABCA1 Agonist CS6253 Reverses apoE4-Driven Alzheimer’s Disease in apoE4 TR Mice and Shows Concomitant Plasma and Brain Apoe and Apoj Changes". The second poster presentation will be presented by Dr. Varun Rawat from University of Southern California and is titled "The Abca-1 Agonist (CS-6253) Reverses ApoE4 Hypolipidation in Alzheimer’s Disease".
Poster Title: The ABCA1 Agonist CS6253 Reverses apoE4-Driven Alzheimer’s Disease in apoE4 TR Mice and Shows Concomitant Plasma and Brain Apoe and Apoj Changes
Session Title: Preclinical Therapeutics
Session Date: Sunday, July 16, 2017
Location: S8 P1-076
Poster Title: The Abca-1 Agonist (CS-6253) Reverses ApoE4 Hypolipidation in Alzheimer’s Disease
Session Title: Clinical Therapeutics
Session Date: Wednesday, July 19, 2017
Location: S8 P4-010
May 5, 2017
Dr. Johansson will present at ATVB/PVD 2017 Scientific Sessions. The oral presentation is titled "ABCA1 Agonist CS6253 Reverses Apoe4-driven Alzheimer’s Disease with Concomitant Changes in Plasma and Brain Apoe and Apoj".
Session Title: Lipoprotein Metabolism and Therapeutic Targets
Session Date: Friday, May 5, 2017
Presentation Time: 10:30 AM - 10:45 AM
Location: Nicollet Ballroom A, Hyatt Regency Minneapolis, Minnesota.
March 30 & April 1, 2017
Prof. Danny Michaelson and his lab will present new exciting data regarding CS6253 during AD/PD in Vienna, Austria. The oral presentation is named "The role of hypolipidation in mediating the pathological effects of apoE4" and scheduled for March 30th, at 10.15am in Hall B. A poster presentation will be available to view and discuss on April 1st in the galleria (poster# 337). The poster is titled "Differential effects of apoE4 and activation of ABCA1 on brain and plasma lipoproteins".
March 27, 2017
Dr. Johansson will present at the Cambridge Healthtech Institute's Peptide Discovery and Development meeting during the peptides for CNS and cardiovascular session. The title of the presentation is "The CS6253 ABCA1 Agonist Peptide Reverses apoE4 Alzheimer’s Disease".
November 14, 2016
Artery's poster abstract "ABCA1 Agonist Treatment Of ApoE4 Driven Alzheimers‘S Disease, Effects On Serum ApoE Distribution, Brain Phenotype And Cognition" has been accepted to the American Heart Association Scientific Sessions 2016 in New Orlease, LA.
Session Title: HDL and the Artery Wall
Poster: M1006 / 1006
Session Date: Monday, November 14, 2016
Presentation Time: 12:45 PM - 2:00 PM
Location: Science and Technology Hall-Basic Science Section, New Orleans Ernest N. Morial Convention Center, New Orleans, Louisiana.
September 26, 2016
Dr. Johansson will present at the The Boulder Peptide Symposium 2016. He will discuss Cogpep in the treatment of apoE4 associated Alzheimer's disease. The presentation will be on Monday afternoon at St Julien Hotel, Boulder, Colorado.
July 24, 2016
Artery will present at Alzheimer's Association International Conference (AAIC) in Toronto, Canada. The topic of the oral presentation is "The Novel apoE4 Therapeutic CS6253 Penetrates the Blood Brain Barrier, Upregulates the ABCA1 Transporter and Prevents Alzheimer’s Disease Pathogenesis".
Session Date: Sunday, July 24, 2016
Presentation Time: 2:45 PM - 3:00 PM
Location: Centre Room: 718, Metro Toronto Convention Centre, Toronto, Canada.
June 16, 2016
Danny Michaelson will present at the Lipoprotein Metabolism Gordon Research Conference in Waterville Valley, NH. The title of the presentation is"ABCA1 Directed Treatment of ApoE4 Driven Neurodegeneration in Alzheimer's Disease".
May 5, 2016
Dr. Johansson will present at ATVB/PVD 2016 Scientific Sessions. The presentation title is "The Anti-atherosclerosis ABCA1 Agonist CS6253 Confer Glucose Control by Improved Pancreas Beta-cell Insulin Secretion and Enhanced Peripheral Insulin Utility".
April 25, 2016
Dr. Johansson is scheduled to present at 2016 Diabetes Summit. The title of the oral abstract is "The Candidate Drug CS6253 is an ABCA1 Agonist with Anti-diabetic and Atherosclerosis Reduction Actions" and will be held 3.40pm on April 25 in Boston, MA.
March 10, 2016
Danny Michaelson has been invited to present a "state of the art lecture" at the 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy. Dr. Michaelson topic is "APOE4: The most prevalent yet understudied risk factor for Alzheimer’s disease" and he will discuss Cogpep and its benefits.
Session Date: Thursday, March 10, 2016
Presentation Time: 8:30 AM - 8:50 AM
Location: Room HESPERIDES of the Hilton Athens Hotel, Athens, Greece.
January 12, 2016
Jonas Johansson will present "ABCA1 Agonists Therapeutics for ApoE4 Neurodegenerative Diseases (Alzheimer’s, LBD, TBI), and Diabetes-generated Cardiovascular Disease" at Life Science Nation’s “RESI Innovation Challenge” event at Marines’ Memorial Club & Hotel in San Francisco between 9am and 5pm.
November 9, 2015
Artery Therapeutics, Inc. will present a poster abstract at American Heart Association's Scientific Sessions 2015 in Orlando. The title is "Mechanistic Studies of HDL Mimetic Peptide ATI-5261 Reveal Aspects of Class A Alpha-helix Structure that Induce Cytotoxicity and Hypertriglyceridemia in vivo: Design of Safe Analogs With Potent Anti-atherosclerosis and Anti-diabetic Actions".
Session Title: Best of AHA Specialty Conferences: ATVB 2015
Poster 148
Session Date: Monday, November 9, 2015
Presentation Time: 9:30 AM - 11:00 AM
Location: Exhibit Hall A2 of the The Orange County Convention Center, Orlando, Florida.
October 17, 2015
Anat Boehm-Cagan from The Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel will present "Counteracting impaired lipidation of apoE4 and the associated brain pathology and cognitive deficits by the ABCA1 agonist peptide CogpepB" at Society for Neuroscience.
Session Title: Alzheimer's Disease: Experimental Therapeutics
Session Date: Saturday, October 17, 2015
Presentation Time: 3:00am - 3:15 PM
Location: Room S403, McCormick Convention Center, Chicago, IL.
July 20, 2015
Jan Johansson will present a poster abstract at Alzheimer's Association International Conference 2015. The presentation is named "Correction of apoE4 Dysfunction and Reversal of Alzheimer’s Disease Phenotype and Cognition in ApoE4 Target Replacement Mice By Cogpepb, an ABCA1 Agonist Peptide Derived from the Lipid Binding Segment of ApoE".
Session Title: Target identification and validation studies: Cognitive enhancement and other behavioral symptoms
Poster P2-309
Session Date: Sunday, July 20 7, 2015
Presentation Time: 9:30am - 4:15 PM
Location: Exhibit Hall D of The Walter E. Washington Convention Center, Washington, D.C.
June 7, 2015
John Bielicki will present an oral abstract at American Diabetes Association Scientific Sessions. The presentation is named "Design Features for Creating Safe and Effective HDL Mimetic Peptides with Antidiabetic and Antiatherosclerosis Actions: Studies of ATI-5261 and Its Analogs".
Session Title: New Concepts and Treatments of Diabetic Dyslipidemia
Session Date: Sunday, June 7, 2015
Presentation Time: 5:30-5:45 PM
Location: Room 156 at Boston Convention and Exhibition Center, 415 Summer Street, Boston, Massachusetts.
May 8-10 2015
Artery Therapeutics, Inc. is scheduled to present at ATVB 2015 and its satellite meeting named 5th Annual Spring HDL Workshop. The first oral abstract presentation will be presented by John Bielicki on Friday May 8th at 10:45 am. The topic is "Mechanistic Studies of HDL Mimetic Peptide ATI-5261 Reveal Aspects of Class A Alpha-helix Structure that Induce Cytotoxicity and Hypertriglyceridemia In vivo: Design of Safe Analogs with Potent Anti-atherosclerosis and Anti-diabetic Actions".
Anouar Hafiane, McGill Univ, Montreal, Canada will present poster # 650 at the Poster Session III: Saturday, May 9, 8:30–10:30 am. The poster is titled "Characterization of Microparticles Formed by ABCA1".
On Sunday, May 10th John Bielicki will present between 11:00-11:30 am at the Spring Workshop on HDL. During session 5: PRE-BETA HDL: FRIEND OR FOE? The topic of the presentation and discussion is “Pre β HDL as a mechanistic component and marker of HDL functional therapy: studies of mimetic peptides”.
All events will be held at Hilton San Francisco Union Square Hotel.
March, 2015
Highly relevant to the the ABCA`1 agonist and CogpepB Alzheimer’s Disease (AD) medicine exciting new data is being presented in March at two back-to-back meetings in the US and Europe.
Firstly, at the American Society for Neurochemistry, Atlanta, GA, March 17, 2015, 3:30-5:30 pm the R. Wayne Albers Memorial Symposium focus on ABCA1 as a target for AD with some CogpepB data being presented, see program below;
Symposium 24 - Modulation of ABC Transporters and APOE Levels as Therapeutic Targets for Alzheimer’s, Chair: Danny Michaelson, Co-Chair: Mary Jo LaDu
KEY FUNCTIONS OF ABCA1 IN MULTIPLE TISSUES, John Parks, Winston-Salem
THE THERAPEUTIC POTENTIAL OF ABCA1 FOR ALZHEIMER DISEASE Cheryl Wellington, Vancouver
APOLIPOPROTEIN E LIPIDATION AS A MECHANISTIC THERAPEUTIC TARGET FOR LOWERING SOLUBLE AMYLOID-β LEVELS IN ALZHEIMER’S DISEASE, Mary Jo LaDu, Chicago
ABCA1 DIRECTED TREATMENT OF APOE4 DRIVEN NEURODEGENERATION IN ALZHEIMER’S DISEASE, Danny Michaelson, Tel Aviv
Secondly, at the Alzheimer’s Disease Parkinson’s Disease (ADPD) meeting in Nice, France, CogpepB data will be presented in two oral presentations;
March 18, 11:40 - 12:00 ABCA1 AGONIST PEPTIDES: A NEW THERAPEUTIC AVENUE FOR THE TREATMENT OF ALZHEIMER'S DISEASE, A. Boehm-Cagan, Israel
March 20, 18:35 - 18:55 APOE4 TARGETED PHARMACOLOGICAL AND IMMUNOLOGICAL THERAPY OF ALZHEIMER'S DISEASE, Daniel M. Michaelson, Israel.
January 13, 2015
Jonas Johansson will present at Life Science Nation’s “Redefining Early Stage Investment” event at Marines’ Memorial Club & hotel in San Francisco between 9 and 4pm.